智通财经APP讯，先声药业(02096)发布公告，集团自主研发的双特异性抗体偶联药物(BsADC)候选新药SIM0610已获得中国国家药品监督管理局签发的药物临床试验批准通知书，拟开展针对局部晚期╱转移性实体瘤患者的临床试验。
SIM0610是一款同时靶向表皮生长因子受体(EGFR)和间质表皮转化因子(cMET)的BsADC，通过内化释放拓扑异构酶I抑制剂(TOP1i)诱导肿瘤细胞凋亡。EGFR与cMET在非小细胞肺癌等多种实体瘤中异常激活，其中cMET激活是表皮生长因子受体络氨酸激酶抑制剂(EGFR-TKI)产生耐药性的重要机制之一。 SIM0610通过双靶点协同作用，有望增强抗肿瘤活性并克服耐药。临床前研究显示，SIM0610在多种肿瘤模型中表现出显著的抗肿瘤活性。
该公司是一家创新与研发驱动的制药公司，建设有“神经与肿瘤药物研发全国重点实验室”。该公司聚焦神经科学、抗肿瘤、自身免疫及抗感染领域，同时积极前瞻性布局未来有重大临床需求的疾病领域，履行“为患者而生”的企业使命。公司以自主研发及协同创新双轮驱动，与多家创新企业、科研院校建立战略合作伙伴关系。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.